WSCM
LCTX icon

Wellington Shields Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Wellington Shields Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-338,250
Closed -$857K – 348
2014
Q3 		$857K Buy
338,250
+156,735
+86% +$377K 0.14% 150
2014
Q2 		$447K Buy
+181,515
New +$410K 0.07% 236

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Destination Wealth Management
Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Wellington Shields Capital Management's LCTX Position: Q4 2014 in Review

Wellington Shields Capital Management sold out of Lineage Cell Therapeutics (LCTX) in Q4 2014, closing a stake of 338,250 shares — an estimated $857K sold.

Wellington Shields Capital Management first reported a position in LCTX in Q2 2014 and held it in 2 quarters. The position peaked at $857K in Q3 2014. 59 funds tracked by Wall St. Rank hold LCTX as of Q4 2014.

  • Wellington Shields Capital Management reported no remaining Lineage Cell Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Wellington Shields Capital Management sold 338,250 Lineage Cell Therapeutics shares in Q4 2014, an estimated $857K.
  • Wellington Shields Capital Management first reported a position in Lineage Cell Therapeutics in Q2 2014 and held it in 2 quarters.
  • Wellington Shields Capital Management's Lineage Cell Therapeutics position peaked at $857K in Q3 2014.
  • 59 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2014.

Based on Wellington Shields Capital Management's 13F filing for Q4 2014, filed 12 Feb 2015.